Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) EBT Margin (2020 - 2025)

Historic EBT Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to 108.45%.

  • Maravai Lifesciences Holdings' EBT Margin rose 1409400.0% to 108.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 113.31%, marking a year-over-year decrease of 2725600.0%. This contributed to the annual value of 100.89% for FY2024, which is 3146800.0% down from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' EBT Margin is 108.45%, which was up 1409400.0% from 156.39% recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year EBT Margin high stood at 885.05% for Q4 2023, and its period low was 249.39% during Q3 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' median EBT Margin value was 5.72% (recorded in 2023), while the average stood at 29.84%.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' EBT Margin surged by 8382200bps in 2023 and then crashed by -9665100bps in 2024.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' EBT Margin stood at 63.34% in 2021, then decreased by -26bps to 46.83% in 2022, then skyrocketed by 1790bps to 885.05% in 2023, then plummeted by -109bps to 81.46% in 2024, then plummeted by -33bps to 108.45% in 2025.
  • Its EBT Margin stands at 108.45% for Q3 2025, versus 156.39% for Q2 2025 and 112.47% for Q1 2025.